Compare Gilead Sciences, Inc. (GILD) vs CarMax, Inc (KMX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs CarMax, Inc — how do they compare? Gilead Sciences, Inc. trades at $136.55 (market cap $163.51B), while CarMax, Inc trades at $58.47 (market cap $8.36B). The key difference: Gilead Sciences, Inc. is far larger — about 19.6× CarMax, Inc's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while CarMax, Inc pays none. Which is the better fit depends on your goals.
| GILD | KMX | |
|---|---|---|
Market Cap | $163.51B | $8.36B |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $63.53 |
52-Week Low | $108.22 | $30.88 |
Enterprise Value | $178.05B | $26.87B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
CarMax (KMX) stock trades at $59.87, up 7.43% in the last session, with a bullish technical signal from moving averages. The company reported Q1 2026 earnings that beat expectations, with revenue of $26.35 billion and net income of $500.56 million in 2025. However, net income margin remains thin at 0.84%, and the stock trades at a P/E of 36.61, which is elevated relative to historical norms. Recent news highlights a four-pillar strategic turnaround under new CEO Keith Barr, though an ongoing legal investigation adds uncertainty.
The outlook for KMX hinges on successful execution of its growth strategy amid a challenging used car market. Upside potential exists if cost controls and digital initiatives improve profitability, but risks include high debt levels, margin pressure, and the pending legal probe. Analyst consensus is mixed, with a Hold rating predominant and a price target of $48.91 below the current price, suggesting caution despite recent positive momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About CarMax, Inc
CarMax sells, finances, and services used and new cars through a chain of over 230 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue and wholesale about 13%, with the remaining portion composed of extended service plans and repair. In fiscal 2022, the company retailed and wholesaled 924,338 and 706,212 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the U.S. but still estimates that it has only about 4% U.S. market share of vehicles 0-10 years old in 2021. It seeks over 5% share by the end of calendar 2025 and revenue between $33 billion to $45 billion by fiscal 2026. CarMax is based in Richmond, Virginia.
Read more on KMX →
